: Verve Therapeutics started at hold with $58 stock price target at Stifel Nicolaus

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Verve Therapeutics Inc.

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply